Day: June 8, 2021

8 June 2021, 14:15 CET The Annual General Meeting and Extraordinary General Meeting (‘General Meetings’) of shareholders of ArcelorMittal (‘the Company’) held today approved all resolutions by a strong majority. Over 73.5% of the voting rights were represented at the General Meetings. In view of the Covid-19 outbreak, the Board of Directors of ArcelorMittal had decided to hold this year’s General Meetings by virtual-only format, as permitted by Luxembourg law. The meeting was preceded by a virtual one-hour Q&A session with shareholders. Arrangements were made to allow shareholders to vote electronically and by proxy voting. The results of the votes will be posted shortly on https://corporate.arcelormittal.com under ‘Investors – Equity investors – Shareholders events – AGM – General Meetings of shareholders, 8 June 2021’ where the...

BION-1301 has been well-tolerated to date in patients with IgAN, with no serious adverse events (SAEs) or treatment discontinuations due to adverse eventsPharmacokinetics (PK) of BION-1301 observed in patients with IgAN are consistent with those previously reported in healthy volunteers and are sufficient to drive rapid and sustained reductions in free APRIL levelsBION-1301 has durably reduced Gd-IgA1, IgA, IgM, and to a lesser extent, IgG levels in patients with IgANBION-1301 has demonstrated a clinically meaningful mean reduction in 24-hour proteinuria (UPCR) in the first several patients enrolled in the study, providing initial proof-of-concept for BION-1301 in IgANChinook to host investor conference call and webcast today at 4:00 pm EDT with Jonathan Barratt, Ph.D., the Mayer Professor of Renal Medicine at University of LeicesterSEATTLE,...

Englewood Cliffs, NJ, June 08, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased to announce that it has entered into a Scientific Research Agreement (SRA) with the University of California San Francisco (UCSF). This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain.  Eric Weisblum, CEO of Silo Pharma commented “Inflammation is a common mechanism across numerous physical diseases. Inflammation has specifically been implicated in the pathophysiology of Parkinson’s Disease, chronic pain, and bipolar disorder.  Psilocybin and related compounds have...

Global results show 90% of patients are in favor of a saliva-based glucose test NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) — GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced survey results from more than 300 patients globally as part of its development and go-to-market strategy. As GBS is advancing to clinical trials of its saliva glucose biosensor, it conducted a global voice of customer survey of diabetes patients to verify the desirability, discuss the applications in daily life and review the product features of its Saliva Glucose Biosensor. The comprehensive global survey featuring more than 300 patients worldwide living with diabetes revealed strong support for a non-invasive alternative...

Splash Beverage Group Inc.Splash Beverage Group Inc. announces uplist to NYSE American Exchange.Splash Beverage Group Inc.Splash Beverage Group Inc. announces uplist to NYSE American Exchange.Fort Lauderdale, Fla, June 08, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Splash Beverage Group, Inc. (OTCQB: SBEV) (the “Company”) (https://www.SplashBeverageGroup.com), a portfolio company  of leading  beverage brands, announces today that, subject to meeting all requirements (including the price requirement) at the time of listing, the Company has been approved to uplist to the NYSE American Exchange in conjunction with an underwritten public offering and one-for-three  reverse stock split of the Company’s common stock effective June 11, 2021. The ticker for the Company’s common stock will remain...

SAINT LAURENT, Quebec, June 08, 2021 (GLOBE NEWSWIRE) — IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it has entered into a Materials Transfer Agreement (the “Agreement”) with an undisclosed global veterinary health company (the “Partner). Pursuant to the Agreement, the Partner will evaluate IntelGenx’s proprietary VetaFilm™ platform in cats. Based on a successful evaluation, IntelGenx and the Partner will enter into negotiations for a commercial agreement in the veterinary field. “This Agreement with a large, multinational animal health company represents IntelGenx taking another major step toward establishing our proprietary VetaFilm™ oral thin film drug delivery platform as a new standard for pets in the future,” said Dr. Horst G. Zerbe, CEO of IntelGenx. About...

MCCARRAN, Nev., June 08, 2021 (GLOBE NEWSWIRE) — Aqua Metals, Inc. (NASDAQ: AQMS) (“Aqua Metals” or the “Company”), which is reinventing metals recycling with its AquaRefining™ technology, announced that it will join the Russell Microcap® Index effective June 28, 2021, at the conclusion of the 2021 Russell Microcap® Index’s annual reconstitution. Aqua Metals was identified on the preliminary list of additions that were posted on June 4, 2021. Inclusion in the Russell Microcap® Index provides Aqua Metals with automatic inclusion in appropriate growth and value indexes. FTSE Russell determines membership for its indices primarily by objective, market-capitalization rankings and style attributes. Steve Cotton, President and CEO of Aqua Metals stated, “Having Aqua Metals included in the Russell Microcap® Index...